Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.5 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 5.7× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Vanguard Intermediate Term Corporate Bond ETF for 62 Days on average.
| HALO | VCIT | |
|---|---|---|
Market Cap | $12.58B | $72.20B |
Volume | 2,179,278 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $115.22 | $84.82 |
52-Week Low | $61.63 | $77.98 |
Typical Hold Time | 1 Days | 62 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $78.385, up 0.15% with a bearish technical signal from moving averages. The ETF maintains consistent $0.34 dividend payments and shows institutional interest with recent purchases by Engineers Gate Manager LP and HB Wealth Management. Technical indicators show mixed signals with RSI at neutral levels while ADX indicates strong trend momentum.
The ETF offers a compelling 4.8% yield with low 0.03% expense ratio, positioning it favorably against competitors. However, the bearish technical outlook and interest rate sensitivity present near-term risks. Long-term income investors may find value in VCIT's investment-grade corporate bond exposure despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
